3-amino-5-(pyridin-4-yl)-1,2-dihydropyridin-2-one

• ChemBase ID: 1235
• Molecular Formular: C10H9N3O
• Molecular Mass: 187.19796
• Monoisotopic Mass: 187.07456192
• SMILES: O=c1[nH]cc(c2ccncc2)cc1N
• Canonical SMILES: O=c1[nH]cc(cc1N)c1ccncc1
• InChI: InChI=1S/C10H9N3O/c11-9-5-8(6-13-10(9)14)7-1-3-12-4-2-7/h1-6H,11H2,(H,13,14)
• InChIKey: RNLQIBCLLYYYFJ-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 3-amino-5-(pyridin-4-yl)-1,2-dihydropyridin-2-one
• IUPAC Traditional name: 3-amino-5-(pyridin-4-yl)-1,2-dihydropyridin-2-one; amrinone
• Brand Name: Inocor; Amcoral; Cartonic; Cordarex; Cordemcura; Wincoram
• Synonyms: Win 40680; Wincoram; 5-Amino-[3,4'-bipyridin]-6(1H)-one; 3-Amino-5-(4-pyridinyl)-1,2-dihydro-2-pyridone; 5-Amino-1,6-dihydro-6-oxo-[3,4'-bipyridine]; AWD 08-250; Cartonic; Cordemcura; Vesistol; Inocor; 5-Amino-(3,4′-bipyridin)-6(1H)-one; Amrinone; Inamrinone; Amrinona [inn-spanish]; Amrinonum [inn-latin]; Inamrinone lactate; Amrinone; 5-Amino-[3,4'-bipyridin]-6(1H)-one

Database IDs

• CAS Number: 60719-84-8
• EC Number: 262-390-0
• MDL Number: MFCD00083228
• PubChem SID: 24890741; 46504647; 160964695
• PubChem CID: 3698

CALCULATED PROPERTIES

JChem

• Acid pKa: 11.00651
• H Acceptors: 3
• H Donor: 2
• LogD (pH = 5.5): -0.6494792
• LogD (pH = 7.4): -0.57015175
• Log P: -0.5689172
• Molar Refractivity: 53.8903 cm^3
• Polarizability: 19.838974 Å^3
• Polar Surface Area: 68.01 Å^2
• Rotatable Bonds: 1
• Lipinski's Rule of Five: true

ALOGPS 2.1

• Log P: 0.27
• LOG S: -1.52
• Solubility (Water): 5.60e+00 g/l

PROPERTIES

Physical Property

• Solubility: DMSO; Methanol (Sparingly)
• Apperance: Brown Solid
• Melting Point: >240°C (dec.)

Safety Information

• Storage Condition: Refrigerator
• RTECS: DW2500000
• European Hazard Symbols: Toxic (T)
• UN Number: 2811
• German water hazard class: 3
• Hazard Class: 6.1
• Packing Group: 3
• Risk Statements: 25
• Safety Statements: 28-45
• GHS Pictograms: GHS06
• GHS Signal Word: Danger
• GHS Hazard statements: H301
• GHS Precautionary statements: P301 + P310
• Personal Protective Equipment: Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges
• RID/ADR: UN 2811 6.1/PG 3
• Storage Temperature: 2-8°C

Pharmacology Properties

• Gene Information: rat ... Pde3a(50678)
• Mechanism of Action: cAMP agonist; Phosphodiesterase inhibitor

Product Information

• Purity: 95+%
• Application(s): Cardiac inotropic agent

DETAILS

DrugBank - DB01427

• Drug Groups: approved
• Description: Amrinone (or inamrinone) is a type 3 pyridine phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure.
• Indication: Used in the treatment of congestive heart failure.
• Pharmacology: Amrinone is a positive inotropic cardiotonic with vasodilator properties, phosphodiesterase inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.
• Affected Organisms: Humans and other mammals
• Biotransformation: Hepatic.
• Half Life: 5 to 8 hours
• Protein Binding: 10 to 49%
• Elimination: The primary route of excretion in man is via the urine as both inamrinone and several metabolites (N-glycolyl, N-acetate, O-glucuronide and N-glucuronide).
• Distribution: * 1.2 L/kg [normal volunteers]
• External Links: Wikipedia

Sigma Aldrich - A4056

Biochem/physiol Actions
Simple, non-glycoside cardiotonic agent, possibly via its phosphodiesterase III (PDE-III) inhibitory action.1
Simple, non-glycoside cardiotonic agent, possibly via its phosphodiesterase III (PDE-III) inhibitory action.1 Independent of its cardiac effects, amrinone provides protection against ischemia-reperfusion injury in kidney,2 liver,3 and heart.4

Toronto Research Chemicals - A635000

A selective cAMP phosphodiesterase (PDE-3) inhibitor with positive inotropic and vasodilatory activity. Cardiotonic.

REFERENCES

• Benotti, J.R., et al.: N. Engl. J. Med., 21, 1373 (1978)
• Ward, A., et al.: Drugs, 26, 468 (1978)
• Bottorff, M.B., et al.: Pharmacotherapy, 5, 227 (1978)
• U.S. Pat., 1978, 4 107 315; CA, 90, 103844r, (synth)
• Alousi, A.A. et al., Pharmacol. Biochem. Prop. Drug Subst., 1981, 3, 120, (rev, pharmacol)
• Ward, A. et al., Drugs, 1983, 26, 468, (rev, pharmacol)
• Gomez-Parra, V. et al., Arch. Pharm. (Weinheim, Ger.), 1984, 317, 183, (synth)
• Perry, R.S., Drugs of Today (Barcelona), 1984, 20, 381, (rev)
• Robertson, D.W. et al., J. Med. Chem., 1986, 29, 635, (cryst struct)
• Niedrich, H. et al., Pharmazie, 1986, 41, 173; 176; 181, (synth, cryst struct, tautom)
• Landmann, H. et al., Arch. Toxicol., Suppl., 1988, 418, (tox, rev)
• Martindale, The Extra Pharmacopoeia, 30th edn., Pharmaceutical Press, 1993, 663
• Lewis, R.J., Sax's Dangerous Properties of Industrial Materials, 8th edn., Van Nostrand Reinhold, 1992, AOD375